The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Hypersensitivity reactions from taxol.
Abstract
Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of this drug. Of 301 patients treated, 32 patients have had definite (27 patients) or possible (five patients) hypersensitivity reactions to taxol. All but one patient had the reaction from the first or second exposure to this agent. Reactions occurred at a variety of doses and were characterized most frequently by dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes. Thirteen (41%) patients had received premedication designed to prevent such toxicity; nevertheless, they sustained HSRs. Prolonging the drug infusion appears to have somewhat reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany) and the mechanism of these reactions to taxol are unknown. We provide guidelines to prevent or minimize such toxicity and treat reactions if they still occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Self-citationPhase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
Self-citationWiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Self-citationLorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
COMPLEMENT AS A MEDIATOR OF INFLAMMATION
da Silva, W. D., Eisele, J. W., & Lepow, I. H. (1967) · The Journal of Experimental Medicine · doi:10.1084/jem.126.6.1027 · Cited by 197
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky, E. K., Burke, P. J., Karp, J. E., Tucker, R. W., Ettinger, D. S., & Donehower, R. C. (1989) · PubMed · Cited by 196
Self-citationSuspected anaphylactic reaction to Cremophor EL.
Dye, D., & Watkins, J. (1980) · BMJ · doi:10.1136/bmj.280.6228.1353 · Cited by 169
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade
Jacobs, R. L., Rake, G. W., Fournier, D. C., CHILTON, R. J., Culver, W. G., & Beckmann, C. H. (1981) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(81)90170-6 · Cited by 152
Hypersensitivity Reactions to Cancer Chemotherapeutic Agents
Weiss, R. B., & Bruno, S. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-1-66 · Cited by 123
Self-citationPhase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem, J. L., Tutsch, K. D., Simon, K., Alberti, D. B., Willson, J. K. V., Tormey, D. C., Swaminathan, S., & Trump, D. L. (1987) · PubMed · Cited by 102
Self-citationEmergency administration of radiocontrast media in high-risk patients
Greenberger, P. A., Halwig, J. M., Patterson, R., et al. (1986) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(86)90357-x · Cited by 92
Phase I study of taxol using a 5-day intermittent schedule.
Legha, S. S., Tenney, D. M., & Krakoff, I. R. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.5.762 · Cited by 68
VM-26 (Teniposide)-Induced Hypersensitivity and Degranulation of Basophils in Children
Nolle, H., Carstensen, H., & HERTZ, H. (1988) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-198824000-00007 · Cited by 43
Hypersensitivity reactions to teniposide (VM-26): an analysis.
O'Dwyer, P. J., King, S. A., Fortner, C. L., & Leyland-Jones, B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1262 · Cited by 41
Self-citationHypersensitivity reactions from antineoplastic agents
Weiss, R. B., & Baker, J. R. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00144273 · Cited by 31
Self-citation
Cited by
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Self-citation
Metadata
- Authors
- Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B.
- Venue
- Journal of Clinical Oncology
- Published
- 1990-07
- Volume
- 8
- Issue
- 7
- Pages
- 1263-1268
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1935541780
- Cited by
- 1,174
- References
- 16
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.